Research and Development of High-Performance, High-Value-Added Products Using Proprietary Technologies
First written in FY2016. 11 of 18 entries say "Restated". Latest entry: FY2024-Q1.
The whole theme swung hardest in 2021: 1 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Restated".
- FY2024-Q1RestatedAnnual report
「(5) R&D Activities There are no applicable matters.」
This quarter also contained no disclosures concerning material R&D activities, R&D expenses or intellectual property acquisitions. - FY2023RestatedAnnual report
「There were no material R&D activities to report.」
The company continues to state that there are no material R&D activities. - FY2022RestatedAnnual report
「There were no material R&D activities to report.」
No material R&D activities, including R&D expenses or intellectual property acquisitions, were reported. - FY2021SoftenedAnnual report
「There were no material R&D activities to report.」
The company reported no new results for R&D expenses or intellectual property acquisitions and concluded that there were no material R&D activities. - FY2021-Q3SoftenedAnnual report
「Not applicable.」
The company stated that there were no applicable items concerning R&D activities for the quarter. No new results for R&D expenses or intellectual property acquisitions, which had been disclosed previously, were presented, but the company did not state that its R&D policy had been withdrawn. - FY2020AdvancedAnnual report
「The intellectual property rights obtained during the fiscal year comprised 2 patents. As of the end of the fiscal year, the company held 23 patents, 3 design rights and 1 utility model right. R&D expenses for the fiscal year amounted to ¥84 million.」
During the fiscal year, the company obtained 2 patents and held 23 patents, 3 design rights and 1 utility model right. R&D expenses amounted to ¥84 million. - FY2019AdvancedAnnual report
「The intellectual property rights obtained during the fiscal year comprised 1 patent. As of the end of the fiscal year, the company held 23 patents, 3 design rights and 1 utility model right. R&D expenses for the fiscal year amounted to ¥63 million.」
During the fiscal year, the company obtained 1 patent, bringing its patent holdings to 23. R&D expenses amounted to ¥63 million, and the company continues to develop proprietary technologies. - FY2019-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter amounted to ¥52 million. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」
Disclosed R&D expenses of ¥52 million for the cumulative third quarter and stated that there were no material changes in the status of R&D activities. - FY2019-Q1RestatedAnnual report
「The amount spent on research and development activities during the cumulative period of the first quarter was ¥15 million. There were no material changes in the status of the company's research and development activities during the cumulative period of the first quarter.」
R&D expenses for the cumulative first quarter amounted to ¥15 million, and the company stated that there were no material changes in the status of R&D activities. - FY2018AdvancedAnnual report
「The intellectual property rights obtained during the fiscal year comprised 1 utility model right. As of the end of the fiscal year, the company held 22 patents, 3 design rights and 2 utility model rights. R&D expenses for the fiscal year amounted to ¥70 million.」
During the fiscal year, the company obtained 1 utility model right and disclosed its intellectual property holdings and R&D expenses of ¥70 million. It continues to develop proprietary technologies for highly functional, high-value-added products. - FY2018-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter amounted to ¥46 million. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」
R&D expenses for the cumulative third quarter amounted to ¥46 million, and the company stated that there were no material changes in the status of R&D activities. - FY2018-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter amounted to ¥26 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
Disclosed R&D expenses of ¥26 million and stated that there were no material changes in the status of R&D activities. - FY2018-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter amounted to ¥9 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」
Disclosed R&D expenses of ¥9 million for the quarter and stated that there were no material changes in the status of R&D activities. - FY2017AdvancedAnnual report
「As a result, the intellectual property rights obtained during the fiscal year comprised 3 patents. Through the end of the fiscal year, the intellectual property rights obtained comprised 24 patents, 3 design rights and 1 utility model right. R&D expenses for the fiscal year amounted to ¥118 million.」
During the fiscal year, the company obtained 3 patents. Its cumulative intellectual property holdings comprised 24 patents, 3 design rights and 1 utility model right, while R&D expenses amounted to ¥118 million. - FY2017-Q3RestatedAnnual report
「R&D spending during the cumulative third-quarter period was ¥107 million. There were no material changes in the status of the Company's R&D activities during the cumulative third-quarter period.」
Reported R&D expenses of ¥107 million and stated that there were no material changes in the status of R&D activities. - FY2017-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter amounted to ¥72 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
Reported R&D expenses of ¥72 million and stated that there were no material changes in the status of R&D activities. - FY2017-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter amounted to ¥43 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」
Reported quarterly R&D expenses of ¥43 million and stated that there were no material changes in the status of R&D activities. - FY2016First statedAnnual report
「As Charle, committed to beauty and health, we have actively developed proprietary technologies in our pursuit of Charle's distinctive approach to manufacturing and our aim of providing highly functional, high-value-added products that meet the needs of more customers. As a result, the intellectual property rights obtained during the fiscal year comprised 2 patents. Through the end of the fiscal year, the intellectual property rights obtained comprised 21 patents, 3 design rights and 1 utility model right.」
The company reported the number of intellectual property rights obtained and R&D expenses of ¥86 million.